核黄素磷酸钠防治鼻咽癌同期放化疗黏膜炎的临床观察

Clinical Observation of Riboflavin Sodium Phosphate on Mucositis Induced by Concurrent Radiochemotherapy on Nasopharyngeal Carcinoma

目的观察核黄素磷酸钠防治鼻咽癌同期放化疗所致黏膜炎和改善体质量下降的临床价值。方法入组中晚期鼻咽癌64例,随机分为两组。观察组同期放化疗开始时即应用核黄素磷酸钠加常规对症处理至放疗结束;对照组治疗期间仅常规对症处理。比较观察两组治疗结束时黏膜炎和体质量下降的程度。结果观察组的黏膜炎治疗结束时评定为Ⅰ、Ⅱ、Ⅲ、Ⅳ级反应的患者分别占12.9%、48.4%、38.7%、0%;而对照组Ⅰ、Ⅱ、Ⅲ、Ⅳ级反应的患者分别占0%、39.4%、54.5%、6.1%。观察组的Ⅰ、Ⅱ、Ⅲ级体质量下降分别占67.7%、32.2%、0%;对照组分别占39.4%、51.5%、9.1%。两组的黏膜炎和体质量下降的差异均有统计学意义(P<0.05)。结论核黄素磷酸钠对鼻咽癌同步放化疗所致黏膜炎有明显的防治作用,并能改善体质量下降的情况。

Objective To evaluate the clinical value of riboflavin sodium phosphate on mucositis induced by concurrent radiochemotherapy for patients with nasopharyngeal carcinoma.Methods Sixty four patients with advanced nasopharyngeal carcinoma were divided into two groups randomly.In the observation group,besides routine supporting treatment,riboflavin sodium phosphate was used from the beginning to the end of radiotherapy,while the patients in the control group received only routine treatment.Mucositis and weight loss was evaluated respectively.Results The incidences of mucositis at grade Ⅰade Ⅱade Ⅲade Ⅳre 12.9%,48.4%,38.7%,0% in the observation group and 0%,39.4%,54.5%,6.1% in the control group,respectively（P0.05）.The incidences of weight loss at grade Ⅰade Ⅱade Ⅲre 67.7%, 32.2%,0% in the observation group and 39.4%,51.5%,9.1% in the control group, respectively（P0.05）.Conclusion The application of riboflavin sodium phosphate may decrease the incidence of mucositis induced by concurrent radiochemotherapy for patients with nasopharyngeal carcinoma,and can improve the condition of weight loss.